2 5 mgkg, during the time of the entire conditioning treatment. LEUKEMIA The recommended dose ranges from 185 mgm2day 5 mgkgday to 481 mgm2day 13 mgkgday divided in one or two daily infusions, administered from 1 up to 2 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mgm2 15 mgkg, during the time of the entire conditioning treatment. THALASSEMIA The recommended dose is 370 mgm2day 10 mgkgday divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mgm210 mgkg, during the time of the entire conditioning treatment.
Posology in paediatric patients
AUTOLOGOUS HPCT:
Solid tumours
The recommended dose in solid tumours ranges from 150 mg/m 2/day (6 mg/kg/day) to 350 mg/m 2/day (14 mg/kg/day) as a single daily infusion, administered from 2 up to 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m 2 (42 mg/kg), during the time of the entire conditioning treatment.
CNS TUMOURS
The recommended dose ranges from 250 mg/m 2/day (10 mg/kg/day) to 350 mg/m 2/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m 2 (42 mg/kg), during the time of the entire conditioning treatment.
ALLOGENEIC HPCT:
Haematological diseases
The recommended dose in haematological diseases ranges from 125 mgm2day 5 mgkgday to 250 mgm2day 10 mgkgday divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 375 mgm2 15 mgkg, during the time of the entire conditioning treatment. LEUKEMIA The recommended dose is 250 mgm2day 10 mgkgday divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mgm2 10 mgkg, during the time of the entire conditioning treatment. THALASSEMIA The recommended dose ranges from 200 mgm2day 8 mgkgday to 250 mgm2day 10 mgkgday divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mgm2 10 mgkg, during the time of the entire conditioning treatment. REFRACTORY CYTOPENIA The recommended dose is 125 mgm2day 5 mgkgday as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mgm2 15 mgkg, during the time of the entire conditioning treatment. GENETIC DISEASES The recommended dose is 125 mgm2day 5 mgkgday as a single daily infusion, administered for 2 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mgm2 10 mgkg, during the time of the entire conditioning treatment. SICKLE CELL ANAEMIA The recommended dose is 250 mgm2day 10 mgkgday divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mgm210 mgkg, during the time of the entire conditioning treatment.
Reconstitution
TEPADINA must be reconstituted with 1.5 ml of sterile water for inj |
